Goldman Sachs Invests Rs 1,125 Crore In Bengaluru-based Biocon Biologics

Bengaluru-based biopharmaceutical company Biocon on October 7 announced an injection of capital worth Rs 1,125 crore ($150 million) by investment giant Goldman Sachs in its subsidiary Biocon Biologics. Goldman will be issued an Optionally Convertible Debentures in return of the investment. The capitalization will help Biocon Biologics invest in its R&D and manufacturing and further expansion in the global market. Interestingly, this is the biggest-ever investment the company has received.